Healthcare Analyst

Wilfred Yuen

Thematic (Sector/Industry)

<ul>
<li>
Sino Biopharm licensed out ex-China rights of PDE3/4 inhibitor for upfront US$200m and obtained the China sales rights for two respiratory products of GSK. See our call takeaways for details
</li>
<li>
China expands National Essential Drug List after 8 years. Per Locust Walk 2Q26 report, China accounted for 60% of licensing deal value and 15% of  biotech VC in 1H26 globally</li>
<li>Other key news include Insilico Medicine (profit alert; rentosertib entering phase 3), Hansoh (B7H3 ADC met primary endpoint), Hengrui (oral GLP-1 positive topline data; FDA declined to approved camrelizumab/rivoceranib)...</li>
</ul>



Sino Biopharm licensed out ex-China rights of PDE3/4 inhibitor for upfront US$200m and obtained the China sales rights for two respiratory products of GSK. See our call takeaways for details


China expands National Essential Drug List after 8 years. Per Locust Walk 2Q26 report, China accounted for 60% of licensing deal value and 15% of  biotech VC in 1H26 globally
Other key news include Insilico Medicine (profit alert; rentosertib entering phase 3), Hansoh (B7H3 ADC met primary endpoint), Hengrui (oral GLP-1 positive topline data; FDA declined to approved camrelizumab/rivoceranib)...


<ul>
<li>We counted 5 license-out/collaboration deals this week: Antengene/K2 on TCE; Insilico/SK Bio on AI-enabled CNS drugs; Abbisko/Lilly on multiple targets; Haisco/Nuvectis on oncology/complement therapies; TrueLab/NewCo on two TL1A-targeting assets.</li>
<li>China approved 4 globally first-in-class therapies on 22 June: Biokin’s EGFR/HER3 ADC for nasopharyngeal carcinoma, CARsgen’s CLDN18.2 CAR-T for gastric cancer, CMS/Genrix’s silevimig for rabies, SBP/ProteLight’s peceleganan for wound infections.</li>
<li>Other news and updates include Hengrui, Ollin/Innovent, Sino Biopharm, Leads Biolabs, Everest, Ascletis.</li>
</ul>


We counted 5 license-out/collaboration deals this week: Antengene/K2 on TCE; Insilico/SK Bio on AI-enabled CNS drugs; Abbisko/Lilly on multiple targets; Haisco/Nuvectis on oncology/complement therapies; TrueLab/NewCo on two TL1A-targeting assets.
China approved 4 globally first-in-class therapies on 22 June: Biokin’s EGFR/HER3 ADC for nasopharyngeal carcinoma, CARsgen’s CLDN18.2 CAR-T for gastric cancer, CMS/Genrix’s silevimig for rabies, SBP/ProteLight’s peceleganan for wound infections.
Other news and updates include Hengrui, Ollin/Innovent, Sino Biopharm, Leads Biolabs, Everest, Ascletis.


China Healthcare Weekly Wrap (22-26 June)

<ul>
<li>
Hengrui's oral GLP-1 HRS7535 released second China phase 3 data in Type 2 diabetes. Moreover, the company's CDK4/6 inhibitor dalpiciclib secured adjuvant breast cancer indication.</li>
<li>
Harbour BioMed and Baidu-backed BioMap to establish next-generation AI-native pipeline company MegaStream, targeting global markets across cardiovascaulr, renal, oncology, and anti-aging disease areas.</li>
<li>Other news and updates include Legend Biotech, Everest Medicines, Henlius, SBP, Insilico Medicine, Novocure/Zai Lab, NovaBridge, IASO Bio, and Abogen.</li>
</ul>



Hengrui's oral GLP-1 HRS7535 released second China phase 3 data in Type 2 diabetes. Moreover, the company's CDK4/6 inhibitor dalpiciclib secured adjuvant breast cancer indication.

Harbour BioMed and Baidu-backed BioMap to establish next-generation AI-native pipeline company MegaStream, targeting global markets across cardiovascaulr, renal, oncology, and anti-aging disease areas.
Other news and updates include Legend Biotech, Everest Medicines, Henlius, SBP, Insilico Medicine, Novocure/Zai Lab, NovaBridge, IASO Bio, and Abogen.


China Healthcare Weekly Wrap (15-21 June)

Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The HSCEI serves as a benchmark to reflect the overall performance of the top 50 "Mainland China" securities listed in Hong Kong.</li>
<li>In this insight, we take a look at the potential index changes and capping flows for HSCEI index rebal event in December 2026.</li>
<li>We expect two ADDs and two DELs for December 2026. We also estimate there to be ~US$118mn in one-way flows including the effects of capping.</li>
</ul>


The HSCEI serves as a benchmark to reflect the overall performance of the top 50 "Mainland China" securities listed in Hong Kong.
In this insight, we take a look at the potential index changes and capping flows for HSCEI index rebal event in December 2026.
We expect two ADDs and two DELs for December 2026. We also estimate there to be ~US$118mn in one-way flows including the effects of capping.


Quiddity Leaderboard HSCEI Dec26: Final Ranks; Two ADDs/DELs Likely; One Change to Expectation

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shenzhen Transsion Holdings / Equity Capital Markets

<ul>
<li>Transsion, a mobile phone maker focused on Africa and other emerging markets, launched its IPO to raise USD 428m through an A+H listing. CITIC is the sole sponsor.</li>
<li>In this note, we look at the deal terms and provide our thoughts on valuation for the company.</li>
<li>We analyze reference A+H transactions, cornerstone and sponsor performance and assess the risk-reward of the deal.</li>
</ul>


Transsion, a mobile phone maker focused on Africa and other emerging markets, launched its IPO to raise USD 428m through an A+H listing. CITIC is the sole sponsor.
In this note, we look at the deal terms and provide our thoughts on valuation for the company.
We analyze reference A+H transactions, cornerstone and sponsor performance and assess the risk-reward of the deal.


Transsion (传音控股) A+H IPO: Analysis of Deal Terms

Hong Kong

Sino Biopharmaceutical is a leading, innovation-driven pharmaceutical conglomerate in China, focusing on the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in therapeutic areas such as oncology, hepatology, respiratory, and cardiovascular diseases, offering both modernized Chinese and Western medicines. It was founded in 2000 and is headquartered in Wanchai, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sino Biopharmaceutical (1177 HK)

China Healthcare Weekly Wrap (6-10 July)

Key news: 1) SBP deals with AZ and GSK, 2) China expands Essential Drug List, 3) clinical/regulatory updates from Hengrui (oral GLP-1; FDA on PD-1...

Wilfred Yuen

China Healthcare Weekly Wrap (22-26 June)

This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Wilfred Yuen

China Healthcare Weekly Wrap (15-21 June)

Hengrui releases China phase 3 data for oral GLP-1 HRS7535 in T2D; Harbour/BioMap for AI- company MegaStream. Other updates: Legend, Everest,...

Wilfred Yuen

Quiddity Leaderboard HSCEI Dec26: Final Ranks; Two ADDs/DELs Likely; One Change to Expectation

Expected DELs Postal Savings Bank (1658 HK) and Shenzhou International (2313 HK) could have 1.7x ADV (~US$45mn) and 0.7x ADV to sell (~US$21mn)...

Janaghan Jeyakumar, CFA

Transsion (传音控股) A+H IPO: Analysis of Deal Terms

We analyze Transsion's USD 428m Hong Kong IPO. We look at deal terms, track records of cornerstone investors and sponsors, as well as its...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China Healthcare Weekly Wrap (6-10 July)

Key news: 1) ​SBP deals with AZ and GSK, 2) China expands Essential Drug List, 3) clinical/regulatory updates from Hengrui (oral GLP-1; FDA on PD-1...

Wilfred Yuen

China Healthcare Weekly Wrap (22-26 June)

​This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Wilfred Yuen

China Healthcare Weekly Wrap (15-21 June)

​Hengrui releases China phase 3 data for oral GLP-1 HRS7535 in T2D; Harbour/BioMap for AI- company MegaStream. Other updates: Legend, Everest,...

Wilfred Yuen

Quiddity Leaderboard HSCEI Dec26: Final Ranks; Two ADDs/DELs Likely; One Change to Expectation

Expected DELs Postal Savings Bank (1658 HK) and Shenzhou International (2313 HK) could have 1.7x ADV (~US$45mn) and 0.7x ADV to sell (~US$21mn)...

Janaghan Jeyakumar, CFA

Transsion (传音控股) A+H IPO: Analysis of Deal Terms

We analyze Transsion's USD 428m Hong Kong IPO. We look at deal terms, track records of cornerstone investors and sponsors, as well as its...

Ke Yan, CFA, FRM

Key news: 1) SBP deals with AZ and GSK, 2) China expands Essential Drug List, 3) clinical/regulatory updates from Hengrui (oral GLP-1; FDA on PD-1...

This week saw 5 license-out/collaboration deals in the biopharma industry and China approving 4 globally first-in-class therapies, with updates...

Hengrui releases China phase 3 data for oral GLP-1 HRS7535 in T2D; Harbour/BioMap for AI- company MegaStream. Other updates: Legend, Everest,...